Evaluation of microhaemagglutination assay to determine treponemal antibodies in CSF.
AUTOR(ES)
Birry, A
RESUMO
The microhaemagglutination assay for Treponema pallidum antibodies (MHA:TP-CSF), the Veneral Disease Research Laboratory (VDRL-CSF), and the fluorescent treponemal antibody (FTA-CSF) tests were used to detect treponemal antibodies in 3157 samples of cerebrospinal fluid from patients with syphilis, with neurological, metabolic, or immunological disorders, and with undetermined diagnoses. An agreement of 99.5% between the results of the MHA:TP-CSF and FTA-CSF tests was obtained for all the CSF samples whereas that of only 95.5% was obtained for samples from the known case of syphilis. The MHA:TP-CSF test is simple, economical, rapid, and specific but not as sensitive as the FTA-CSF test.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1045647Documentos Relacionados
- Further evaluation of the microhaemagglutination test to determine treponemal antibodies in CSF.
- Quantitative microhaemagglutination assay for Treponema pallidum antibodies in humans.
- Quantitative microhaemagglutination assay for Treponema pallidum antibodies in experimental syphilis.
- A rostrocaudal gradient of nitrate plus nitrite concentrations in CSF.
- Herpes zoster meningoencephalitis without rash: varicella zoster virus DNA in CSF.